Abstract #1115

Hyperpolarized 13C Dynamic Breath-held Molecular Imaging to Detect Targeted Therapy Response in Patients with Liver Metastases

Zihan Zhu^1,2, Irene Marco-Rius³, Michael A Ohliger¹, Lucas Carvajal¹, Jeremy W Gordon¹, Hsin-Yu Chen^1,2, Ilwoo Park¹, Peng Cao¹, Peter J Shin¹, Eugene Milshteyn^1,2, Cornelius von Morze¹, Marcus Ferrone⁴, James B Slater¹, Zhen Wang¹, Peder E.Z. Larson¹, Rahul Aggarwal⁵, Robert Bok¹, John Kurhanewicz¹, Pamela Munster⁵, and Daniel B Vigneron¹

¹Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, United States, ²UC Berkeley-UCSF Graduate Program in Bioengineering, UC Berkeley and UCSF, San Francisco, CA, United States, ³University of Cambridge, United Kingdom, ⁴Department of Clinical Pharmacy, UCSF, San Francisco, CA, United States, ⁵Department of Medicine, UCSF, San Francisco, CA, United States

New clinical trials are using hyperpolarized ¹³C molecular imaging technology to evaluate tumor metabolic activity and response to targeted drug therapies. The goal of this work was to develop and apply an experimental setup for HP ¹³C MR investigations of cancer metastases to liver. In this study, patients with liver metastases were imaged and the results demonstrated sufficient SNR and data quality for the quantification of the localized conversion rate of [1-¹³C]pyruvate to [1-¹³C]lactate through lactate dehydrogenase (LDH), which is a pathway targeted by numerous emerging pharmaceutical agents and currently prescribed Everolimus.

This abstract and the presentation materials are available to members only; a login is required.

Join Here